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Abstract
Background: Cholesteryl ester transfer protein (CETP) plays a major role in lipid metabolism, but studies on the
association of CETP polymorphisms with risks of cardiovascular disease are inconsistent. This study investigated
whether the CETP gene I405V and Taq1B polymorphisms modified subclinical atherosclerosis in an asymptomatic
Brazilian population sample.
Methods: The polymorphisms were analyzed using polymerase chain reaction in 207 adult volunteers. Serum lipid
profiles, oxLDL Ab titers, C-reactive protein and tumor necrosis factor-α concentrations and CETP and phospholipid
transfer protein (PLTP) activities were determined, and common carotid artery intima-media thickness (cIMT) was
measured using ultrasonography.
Results: No differences in cIMT were observed between the presence or absence of the minor B2 and V alleles in
either polymorphism. However, inverse correlations between mean cIMT and CETP activity in the presence of these
polymorphisms were observed, and positive correlations of these polymorphisms with PLTP activity and oxLDL Ab
titers were identified. Moreover, logistic multivariate analysis revealed that the presence of the B2 allele was
associated with a 5.1-fold (CI 95%, OR: 1.26 – 21.06) increased risk for cIMT, which was equal and above the 66th
percentile and positively interacted with age. However, no associations with the V allele or CETP and PLTP activities
were observed.
Conclusions: None of the studied parameters, including CETP activity, explained the different relationships
between these polymorphisms and cIMT, suggesting that other non-determined factors were affected by the
genotypes and related to carotid atherosclerotic disease.
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Background
Atherosclerotic disease is a complex multifactorial
process that leads to the deposition and accumulation of
cholesterol along the arterial wall [1]. Cholesteryl ester
transfer protein (CETP) plays a major role in cholesterol
metabolism [2], and polymorphisms within this gene
may underlie the susceptibility to atherosclerosis [3].
The I405V (rs5882) and Taq1B (rs708272) polymorph-
isms and their respective minor alleles, V and B2, are
associated with decreased CETP activity and increased
high-density lipoprotein cholesterol (HDL-C) levels [4].
However, studies on the association of these polymorph-
isms with risks of cardiovascular disease (CVD) are in-
consistent [5], and their association with subclinical
CVD are less well characterized.
Therefore, this study investigated whether I405V and
Taq1B polymorphisms modified subclinical atherosclerosis
in an asymptomatic Brazilian adult sample population.
Methods
Study subjects
A total of 207 asymptomatic volunteers of both sexes
(20–75 years) were recruited at the Lipid Outpatient
Clinic at the State University (Unicamp) Hospital in
Campinas, SP, Brazil.
The following exclusion criteria were used: body mass
index (BMI) ≥ 30 kg/m2; a diagnosis of endocrinological,
liver or kidney disease; use of drugs that alter the lipid
profile; excessive use of alcohol (>75 g/day) [6]; meeting
the “present CVD” criteria (acute myocardial infarction
and angina pectoris, as established by electrocardiogram,
cardiac-specific enzyme levels, coronary angiography
and/or a history of coronary angioplasty or myocardial
revascularization).
The local Medical School Ethics Committee approved this
study, and all participants signed an informed consent form.
Biochemical analysis
The following blood measurements were performed
using Roche Diagnostics (Mannheim, Germany) reagents
in an automated system: total cholesterol (CHOD-PAP),
triglycerides (TG, GPO-PAP), HDL-C (HDL-C plus 3rd
generation), low-density lipoprotein cholesterol (LDL-C
plus 2nd generation for TG >400 mg/dL and Friede-
wald’s equation for TG ≤ 400 mg/dL). Apolipoproteins
AI (NAS-ApoA1), B100 (NAS-ApoB) and lipoprotein (a)
were obtained from Siemens (USA). C-reactive protein
(CRP) was measured using the Tina-quantW CRP (latex)
high sensitivity assay (Roche Diagnostics, Switzerland).
Plasma levels of tumor necrosis factor α (TNF-α) were
measured using ELISA (Cayman Chemical, USA).
HDL2 and HDL3 sub-fractions were obtained using se-
quential micro-ultracentrifugation [7].
CETP [8] and phospholipid transfer protein (PLTP) ac-
tivities [9] in plasma were determined using radioassays
with exogenous substrates.
Antibodies against oxidized LDL (oxLDL Ab) titers
were determined using an in-house ELISA [10].
Polymorphism detection
Genomic DNA was extracted [11] and amplified using
polymerase chain reaction to identify the Taq1B [12] and
I405V [13] polymorphisms.
Measurement of cIMT
A single trained sonographer, who was blind to the sub-
ject’s identity, performed high-resolution B-mode com-
mon carotid ultrasonography using a 6–9 MHz linear
array ultrasound imaging system (ATL HDI 1500 Ultra-
sound System, Advanced Technology Laboratories
Ultrasound, USA). Longitudinal measurements of seg-
ments of the common carotid arteries at the distal wall
and 1 cm from the bifurcation were performed accord-
ing to a standardized method [14]. The mean common
carotid artery intima-media thickness (cIMT) was calcu-
lated as the average of five measurements on each side
(right and left) and expressed in millimeters.
Statistical analysis
Mann–Whitney U and Chi-Squared tests compared vari-
ables, and the Spearman test was performed for correla-
tions. Univariate and multivariate logistic regression
analyses, with stepwise criteria of the variables of inter-
est, the presence of the V and B2 allele, gender, age,
HDL-C, BMI and systolic blood pressure (SBP), were
performed to verify the relationships of these variables
with higher cIMT values, which was defined as above or
below the established cutoff value of 0.795 mm and cor-
responding to cIMT equal and above the 66th percentile
values of the studied population.
All the analyses were performed using the SASW, version
9.1.3 and SPSS 11.5 for Windows. Haploview, v 4.2© was
used for the linkage disequilibrium (LD) analysis [15].
Results
The frequencies of I405V and Taq1B genotypes in our
population sample, represented by the presence (VV, IV)
and absence (II) of the V allele and the presence (B2B2,
B1B2) and absence (B1B1) of the B2 allele, are presented
in Table 1. The frequencies of the II, IV and VV geno-
types were 28%, 53% and 19%, respectively, and the fre-
quencies of the B1B1, B1B2 and B2B2 were 33%, 41%
and 26%, respectively.
Allele frequencies were consistent with Hardy–
Weinberg equilibrium for the I405V polymorphism
(p=0.36) but not the Taq1B (p=0.02), and the MAFs
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(minor allele frequency) were <45% and <46%, respect-
ively. The linkage disequilibrium between the two poly-
morphisms was very weak, as evidenced by the D`=0.17.
Clinical and anthropometric characteristics and bio-
chemical data of the investigated population are pre-
sented in Tables 2 and 1.
Table 3 presents the significant correlations between
mean cIMT, oxLDL Ab titers and CETP and PLTP
activities.
The univariate analyses (Table 4) indicated that the fe-
male gender, age, HDL-C, BMI and SBP were signifi-
cantly associated (p value ≤0.05) with higher cIMT.
The multivariate analysis (Table 5) demonstrated that
age and the presence of the B2 allele were positively
related to higher cIMT. Individuals with increased risk
exhibited the B2 allele (5.1-fold increase) and higher age
(21.2% increase/each year of age).
A Chi-Square analysis indicated an interaction be-
tween the presence of the B2 allele and age. The com-
bination between age, categorized in ≥ and <50 years
(median value), and the presence or absence B2 allele
formed 4 groups of individuals who were crossed with
cIMTs above and below 0.795 mm (data not shown).
Discussion
This study investigated whether the I405V and Taq1B
polymorphisms modify subclinical atherosclerosis in an
asymptomatic population sample.
Previous studies present controversial data on the role
of Taq1B and I405V in atherosclerosis and CVD. The B2
allele is associated with lower internal carotid artery
IMT in men [16], but other studies do not identify asso-
ciations between the Taq1B polymorphism and cIMT
[17,18]. The present study demonstrated that cIMT did
not differ between either allele of the polymorphisms.
However, inverse correlations between cIMT and CETP
activity were demonstrated in both polymorphisms
(Table 3), which suggest a potential atheroprotective role
for CETP in these individuals. A potential anti-
inflammatory role for CETP was demonstrated previ-
ously [19] wherein the induction of acute inflammation
produced lower mortality due to sepsis and lower cyto-
kine circulation in mice that express human CETP.
Reductions in CETP concentrations in human patients
with sepsis are more pronounced in non-survivors [20].
We identified positive correlations between cIMT and
PLTP and oxLDL Ab in the presence of the V and B2
alleles. Previous studies have suggested that PLTP
Table 1 Biochemical parameters in the presence and
absence of minor alleles
Parameters A. I405V Genotypes
II V carriers p value ≤
(n=32-59) (n=70-148)
Frequency (%) 29 71
CETP (%) 14.5 ± 9.0 11.0 ± 7.2 0.015
HDL-C (mg/dL) 72 ± 24 74 ± 18 0.192
HDL2-C (mg/dL) 15 ± 6 17 ± 6 0.030
PLTP (%) 22.3 ± 11.9 15.8 ± 9.9 0.001
Lipoprotein (a) (mg/dL) 27 ± 30 32 ± 36 0.477
OxLDL Ab (OD) 0.33 ± 0.16 0.38 ± 0.19 0.405
Parameters B. Taq1B Genotypes
B1B1 B2 carriers p value ≤
(n=32-68) (n=70-139)
Frequency (%) 33 67
CETP (%) 13.4 ± 8.2 11.3 ± 7.7 0.103
HDL-C (mg/dL) 74 ± 26 73 ± 16 0.584
HDL2-C (mg/dL) 17 ± 6 17 ± 5 0.657
PLTP (%) 17 ± 11 18 ± 11 0.860
Lipoprotein (a) (mg/dL) 24 ± 30 33 ± 36 0.014
oxLDL Ab (OD) 0.33 ± 0.17 0.38 ± 0.18 0.230
Data are presented as means ± standard deviation; (sample number): n =
minimum and maximum of subjects with determined parameters; p values:
Mann–Whitney U test for comparisons between the presence and absence of
the minor alleles (V and B2). Significant differences: p≤0.05 in bold. CETP (%) =
activity of cholesterol ester transfer protein; HDL-C = high-density lipoprotein
cholesterol; PLTP (%) = activity of phospholipid transfer protein; oxLDL Ab =
antibodies against oxidized LDL titers; (OD)= optical density.
Table 2 Clinical and anthropometric characteristics in the
presence and absence of minor alleles
Parameters A. I405V Genotypes
II V carriers p value ≤
(n=34-59) (n=83-148)
Age (years) 47 ± 14 49 ± 15 NS
Male (%) 24 26 NS
BMI (kg/m2) 25 ± 6 25 ± 5 NS
WC (cm) 76 ± 11 81 ± 12 0.008
SBP (mmHg) 120 ± 13 127 ± 16 0.002
DBP (mmHg) 77 ± 10 82 ± 10 0.001
Mean cIMT (mm) 0.74 ± 0.19 0.79 ± 0.23 NS
Parameters B. Taq1B genotypes
B1B1 B2 carriers p value ≤
(n=37-68) (n=80-139)
Age (years) 49 ± 15 48 ± 14 NS
Male (%) 35 21 0.026
BMI (kg/m2) 25 ± 4 25 ± 6 NS
WC (cm) 81 ± 12 79 ± 12 NS
SBP (mmHg) 127 ± 14 124 ± 16 NS
DBP (mmHg) 82 ± 11 79 ± 10 NS
Mean cIMT (mm) 0.73 ± 0.20 0.79 ± 0.23 NS
Data presented as means ± standard deviation; (sample number): n =
minimum and maximum of subjects with determined parameters; p values =
Mann–Whitney U test for comparisons between the presence and absence of
the alleles (V and B2); gender comparisons, Chi-Square test. Significant
differences: p≤0.05 in bold. BMI= Body Mass Index; WC= waist circumference;
SBP= systolic blood pressure; DBP= diastolic blood pressure; cIMT= carotid
intima-media thickness.
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increases the risk of cardiovascular disease in humans
[21], and the balance of evidence suggests a pro-
atherogenic role for oxLDL Ab titers [22] in the devel-
opment of atherosclerosis. These positive correlations
and the lack of correlations of these variables in both
common B1B1 and II allele homozygotes (CETP
p≤0.318 and 0.091, oxLDL Ab p≤ 0.709 and 0.386 and
PLTP p≤0.823 and 0.470, respectively) (data not shown)
suggest a possible pro-atherogenic role of these markers
associated with the polymorphisms. Our sample size was
relatively small and different between groups. Therefore,
further studies are underway in our lab to further con-
firm these correlations.
The presence of the V allele was associated with lower
CETP (24%) and PLTP (29%) activities and higher
HDL2-C (13%) concentrations. Patients with coronary
disease typically exhibit fewer large HDL particles
(HDL2), and the concentration of these large particles is
a better predictor of future cardiovascular events than
HDL-C concentration [23].
Lipoprotein (a) plasma levels were also significantly
increased in the presence of the B2 allele. High levels of
lipoprotein (a) are significantly associated with the pres-
ence, severity and extent of carotid atherosclerosis [24],
but this increase was not observed as a possible pro-
atherogenic factor.
No significant differences in CETP activity and HDL-C
levels were observed in Taq1B polymorphism, despite a
15.4% reduction in CETP activity in presence of the B2
allele. These results are consistent with a previous study
in another Brazilian population, in which no association
between Taq1B genotypes and HDL-C levels was
observed [25].
A univariate analysis (Table 4) followed by a multivari-
ate logistic stepwise analysis (Table 5) demonstrated that
the presence of the B2 allele was independently asso-
ciated with a mean 5.1-fold increased risk for higher
cIMT and age interacted with the allele effect. The pres-
ence of the B2 allele in the ≥ 50 years age group exhib-
ited the highest risk of higher cIMT in the Chi-Square
analysis (data not shown).
The effects of the Taq1B variant on circulating plasma
lipids may be related to other functional mutations
within the CETP gene locus that are in LD [26], which
may explain the association in our study. However, other
factors than the CETP activity may exert different ath-
erosclerotic repercussions in Taq1B and I405V poly-
morphisms. A multivariate analysis was performed to
verify the independence of the associations between the
qualitative binary variable cIMT above or below 66th per-
centile (0.795mm), CETP and PLTP plasma activities
and the potential confounding factors, including gender,
age, BMI, SBP and HDL-C. Only age exhibited a signifi-
cant statistical association (OR: 1.247, CI 95%OR: 1.129 –
1.377), which was a strong determinant of cIMT (data
not shown). The absence of interactions of other tested
parameters with higher cIMT in this study suggests that
Table 3 Significant correlations between cIMT, oxLDL Ab, CETP (%) and PLTP (%) in the presence of minor alleles
cIMT versus V carriers cIMT versus B2 carriers
r p value ≤ r p value ≤
CETP (%) n=88 −0.363 0.0001 CETP (%) n=87 −0.427 0.0001
oxLDL Ab (OD) n=54 0.409 0.002 oxLDL Ab (OD) n=51 0.432 0.002
PLTP (%) n=85 0.322 0.003 PLTP (%) n=84 0.315 0.004
r= Spearman´s coefficient; Significant differences: p≤0.05 in bold. cIMT= carotid intima-media thickness; oxLDL Ab= antibodies against oxidized LDL titers; (OD) =
optical density; CETP(%) = activity of cholesteryl ester transfer protein; PLTP (%) = activity of phospholipid transfer protein.
Table 4 Univariate Logistic Regression analyses for
higher cIMT (above 66 percentile) (n=118)
Variables Categories p value ≤ OR CI 95% OR
Presence of V allele No (ref). 0.303 1.00 —
Yes 1.57 0.67 – 3.69
Presence of B2 allele No (ref). 0.150 1.00 —
Yes 1.87 0.80 – 4.36
Gender Male (ref.) 1.00 —
Female 0.048 2.48 1.01 – 6.10
Age (years) (cont). 0.001 1.195 1.116 – 1.279
HDL-C (mg/dL) (cont). 0.035 1.024 1.002 – 1.047
BMI (kg/m2) (cont). 0.009 1.105 1.025 – 1.191
SBP (mmHg) (cont). 0.003 1.043 1.014 – 1.072
cIMT below and above the 66th percentile, <0.795 (n=76) and >0.795 (n=42),
respectively. (ref).=reference level. (cont).= continue variable. OR= Odds ratio
for higher cIMT, above the 66th percentile value (0.795 mm), CI 95% OR=
Confidence interval of 95% for the Odds ratio. Significant differences: p≤0.05
in bold; B2 = minor allele of Taq1B polymorphism, V = minor allele of I405V
polymorphism, HDL-C = high-density lipoprotein cholesterol, BMI: body mass
index, SBP: systolic blood pressure.
Table 5 Multivariate Logistic Regression* analyses for
higher cIMT (above 66th percentile) (n=114)
Variables Categories p value ≤ OR CI 95% OR
Age (years) (cont). 0.001 1.212 1.126 – 1.304
Presence of B2 allele No (ref). 0.023 1.00 —
Yes 5.14 1.26 – 21.06
*Stepwise criteria for selection of variables. cIMT below and above 66th
percentile, <0.795 (n=73) and >0.795 (n=41), respectively. (ref).= reference
level; (cont).=continue variable. OR= Odds ratio for higher cIMT above the 66th
percentile value (0.795 mm), CI 95% OR= Confidence interval of 95% for Odds
ratio. Significant differences: p≤0.05 in bold; B2 = minor allele of Taq1B
polymorphism.
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other non-determined factors were affected by the geno-
types and related to carotid atherosclerotic disease.
Our results focused on several biomarkers that were
assessed for the first time in the Brazilian population,
and the results were partially based on the correlations
between a relatively small numbers of individuals. These
results merit further exploration due to the high fre-
quency of the investigated polymorphisms in the present
Brazilian sample. Identifying the impact of these poly-
morphisms is an ongoing aim of our research group.
Conclusions
The I405V and Taq1B polymorphisms were differently
associated with subclinical atherosclerosis because only
the presence of the minor B2 allele, but not the V allele,
was independently associated with higher cIMT. We
demonstrated that none of the studied parameters
explained the different relationships between these poly-
morphisms and cIMT, which leads us to speculate that
the association between the B2 allele and cIMT is due to
other non-studied factors. Ongoing studies are underway
in our laboratory to determine the modulation factors
that are involved.
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